BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

...in China in 2020, based on securing reimbursement for Plavix clopidogrel and hypertension drug Co-Aprovel irbesartan/hydrochlorothiazide...
BioCentury | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

...therapy Alimta pemetrexed; and Sanofi (Euronext:SAN; NASDAQ:SNY), which won its bid for hypertension drug Irtra irbesartan/hydrochlorothiazide...
BioCentury | Sep 25, 2019
Politics & Policy

Additional price cuts in nationwide expansion of China’s centralized procurement

...was up RMB0.45 to RMB15.54. The company announced it won bids for seven products: irbesartan, irbesartan/hydrochlorothiazide...
BioCentury | Jul 15, 2013
Clinical News

Aprovel irbesartan regulatory update

...EMA's CHMP recommended updating the labels of hypertension drugs Aprovel irbesartan and CoAprovel irbesartan/hydrochlorothiazide to include...
...aliskiren-containing medicines. In the U.S., Aprovel is marketed as Avapro and CoAprovel is marketed as Avalide...
...also marketed to treat diabetic renal disease in patients with hypertension and Type II diabetes. CoAprovel...
BioCentury | Jul 15, 2013
Clinical News

CoAprovel irbesartan/hydrochlorothiazide regulatory update

...EMA's CHMP recommended updating the labels of hypertension drugs Aprovel irbesartan and CoAprovel irbesartan/hydrochlorothiazide to include...
...aliskiren-containing medicines. In the U.S., Aprovel is marketed as Avapro and CoAprovel is marketed as Avalide...
...Squibb Co. (NYSE:BMY), New York, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: CoAprovel irbesartan/hydrochlorothiazide ( Avalide...
BioCentury | Jan 28, 2013
Finance

Oleg's asymmetry

...the decline to the loss of patent exclusivity for cardiovascular drugs Avapro irbesartan and Avalide irbesartan/hydrochlorothiazide...
BioCentury | Oct 29, 2012
Finance

NextWave's option arithmetic

...the decline to the loss of patent exclusivity for cardiovascular drugs Avapro irbesartan and Avalide irbesartan/hydrochlorothiazide...
BioCentury | Oct 8, 2012
Company News

Bristol-Myers, Sanofi deal

...a 1993 co-promotion deal for three cardiovascular drugs - Plavix clopidogrel, Avapro irbesartan and Avalide irbesartan/hydrochlorothiazide...
...Bristol-Myers will now receive royalties on Sanofi's sales of branded and unbranded Plavix, Avapro and Avalide...
...between the companies, including the one-time payment of $80 million by Bristol-Myers to Sanofi for Avalide...
BioCentury | Oct 4, 2012
Company News

Bristol-Myers, Sanofi amend cardiovascular partnership

...restructured a co-promotion deal for three cardiovascular drugs -- Plavix clopidogrel, Avapro irbesartan and Avalide irbesartan/hydrochlorothiazide...
...Bristol-Myers will now receive royalties on Sanofi's sales of branded and unbranded Plavix, Avapro and Avalide...
...between the companies, including the one-time payment of $80 million by Bristol-Myers to Sanofi for Avalide...
BioCentury | Jul 30, 2012
Finance

HGS in hindsight

...the decline to the loss of patent exclusivity on cardiovascular drugs Avapro irbesartan and Avalide irbesartan/hydrochlorothiazide...
Items per page:
1 - 10 of 21